US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
META
$728.08
▲+0.00%
NVDA
$233.95
▲+0.00%
TSLA
$370.59
▲+0.00%
AMD
$633.91
▲+0.00%
JNJ
$256.03
▲+0.00%
SPCX
$158.96
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
META
$728.08
▲+0.00%
NVDA
$233.95
▲+0.00%
TSLA
$370.59
▲+0.00%
AMD
$633.91
▲+0.00%
JNJ
$256.03
▲+0.00%
SPCX
$158.96
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Neurocrine Biosciences, Inc. - Common Stock
(NQ:
NBIX
)
143.18
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Neurocrine Biosciences, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
April 27, 2026
From
Brodsky & Smith LLC
Via
GlobeNewswire
Neurocrine Biosciences Inc (NASDAQ:NBIX) Combines Strong Fundamentals with a Bullish Technical Setup
↗
April 17, 2026
Via
Chartmill
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Avanos Medical, Inc. (NYSE – AVNS), Leggett & Platt, Incorporated (NYSE – LEG), Soleno Therapeutics, Inc. (Nasdaq – SLNO), Forian, Inc. (Nasdaq – FORA)
April 15, 2026
From
Brodsky & Smith LLC
Via
GlobeNewswire
Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Top Affordable Growth Stock
↗
April 09, 2026
Via
Chartmill
Neurocrine Biosciences Inc. (NASDAQ:NBIX) Presents a Strong Growth and Technical Setup
↗
March 25, 2026
Via
Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Presents a Compelling Case as a Quality Value Stock
↗
March 20, 2026
Via
Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Top GARP Pick with Strong Growth and a Reasonable Price
↗
March 13, 2026
Via
Chartmill
Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal
April 07, 2026
In a move that signals a significant consolidation within the rare endocrine disease market, Neurocrine Biosciences (NASDAQ: NBIX) announced on April 6, 2026, that it has entered into a definitive...
Via
MarketMinute
Neurocrine Biosciences (NBIX): A New Era in Neuroscience and Endocrinology
April 07, 2026
Date: April 7, 2026 Introduction Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has long been a bellwether for the mid-cap biotechnology sector, serving as a primary case study in how a company can...
Via
Finterra
Topics
Earnings
Economy
Intellectual Property
Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit
April 07, 2026
The following feature explores the trajectory of Soleno Therapeutics as of April 7, 2026. Introduction On the morning of April 7, 2026, the biotechnology sector is processing one of the most...
Via
Finterra
Topics
Economy
Intellectual Property
Neurocrine Biosciences Inc (NASDAQ:NBIX) Shows Strong Fundamentals and a Bullish Chart Pattern
↗
February 24, 2026
Via
Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Fits the GARP Strategy with Strong Growth and Reasonable Valuation
↗
February 17, 2026
Via
Chartmill
Wall Street Holds Its Ground While Trump's Iran Deadline Ticks Down
↗
April 07, 2026
Via
Chartmill
Topics
Government
Why Soleno Therapeutics Stock Rocketed Higher on Monday
↗
April 06, 2026
It's being acquired by a peer.
Via
The Motley Fool
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Soleno Therapeutics, Inc. (Nasdaq – SLNO), Affinity Bancshares, Forian, Inc. (Nasdaq – FORA), Janus Henderson Group plc (NYSE - JHG)
April 06, 2026
From
Brodsky & Smith LLC
Via
GlobeNewswire
Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar
April 06, 2026
Shares of Soleno Therapeutics (NASDAQ: SLNO) surged more than 32% in early trading on Monday, April 6, 2026, following the blockbuster announcement that Neurocrine Biosciences (NASDAQ: NBIX) has...
Via
MarketMinute
Topics
Intellectual Property
Neurocrine Biosciences Inc (NASDAQ:NBIX) Screens as a Compelling Value Investment
↗
February 13, 2026
Via
Chartmill
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential
↗
March 23, 2026
This clinical-stage biotech focuses on developing therapies for neurological and immunoscience disorders.
Via
The Motley Fool
Topics
Regulatory Compliance
The Potassium Channel Breakthrough: A Deep-Dive on Xenon Pharmaceuticals (XENE)
March 10, 2026
As of March 10, 2026, the biopharmaceutical sector is witnessing a historic realignment in the neurology space, spearheaded by the Canadian-born clinical powerhouse Xenon Pharmaceuticals Inc. (Nasdaq:...
Via
Finterra
Topics
Economy
Initial Public Offering
Intellectual Property
Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data
↗
February 19, 2026
This biotech specializes in clinical-stage therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.
Via
The Motley Fool
Topics
Regulatory Compliance
Neurocrine Biosciences Inc (NASDAQ:NBIX) Reports Q4 2025 Earnings Miss Amid Strong Annual Sales Growth
↗
February 11, 2026
Via
Chartmill
Topics
Earnings
Neurocrine Biosciences Inc (NASDAQ:NBIX) Presents a Compelling Mix of Strong Fundamentals and Bullish Technical Setup
↗
January 31, 2026
Via
Chartmill
Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead
↗
February 19, 2026
Focused on retinal disease therapies, Kodiak Sciences leads with clinical-stage candidates targeting major unmet needs in ophthalmology.
Via
The Motley Fool
Topics
Regulatory Compliance
This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition
↗
February 19, 2026
This UK-based biotech advances clinical-stage therapies for rare diseases, targeting specialty care markets with a diversified pipeline.
Via
The Motley Fool
CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale
↗
February 19, 2026
This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients with limited treatment options.
Via
The Motley Fool
Topics
Regulatory Compliance
Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Prime Affordable Growth Stock
↗
January 23, 2026
Via
Chartmill
Neurocrine Biosciences Inc. (NASDAQ:NBIX) Presents a Compelling Value Investment Case
↗
January 07, 2026
Via
Chartmill
CRNX Stock Gains, NBIX Shares Drop On Positive Results From Genetics Disorder Trial
↗
January 05, 2026
Via
Stocktwits
BrightSpring Stock Up 86% as Braidwell Takes $45 Million Stake in Healthcare Services Provider
↗
February 19, 2026
BrightSpring Health Services delivers integrated pharmacy and clinical care to Medicare, Medicaid, and insured patients nationwide.
Via
The Motley Fool
Topics
Regulatory Compliance
Neurocrine (NBIX) Q4 2025 Earnings Call Transcript
↗
February 11, 2026
Neurocrine (NBIX) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
